ASX

Encouraging oxide leach recovery for copper & gold at Kharmagtai

Retrieved on: 
Wednesday, March 6, 2024

Upscaled column leach tests, as well as heap leach engineering design work are in progress.

Key Points: 
  • Upscaled column leach tests, as well as heap leach engineering design work are in progress.
  • Recent column leaching tests completed on the mineralised oxide portion of the Kharmagtai Mineral Resource Estimate (MRE) delivered promising metallurgical extraction, peaking at 93% copper and 46% gold.
  • It comprises acid leach to recover and remove cyanide soluble copper, followed by GlyCatTM, which involves a glycine leach to neutralise acid, followed by cyanide leach to recover gold and silver.
  • These are referenced as follows:
    several composite samples collected from White Hill, Stockwork Hill and Copper Hill deposits, and classified as follows: GOX (Green Oxide), SOX (Strong Oxide) and ROX (Red Oxide).

NeoGames Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Wednesday, March 6, 2024

LUXEMBOURG, March 06, 2024 (GLOBE NEWSWIRE) -- NeoGames S.A. (Nasdaq: NGMS) (“NeoGames” or the “Company”), a technology-driven provider of end-to-end iLottery and iGaming solutions, announced today financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • iLottery revenues were $14.4 million during the fourth quarter of 2023, compared to $14.5 million during the fourth quarter of 2022, representing a decrease of (0.4)% year-over-year.
  • In addition, the Company’s share in NPI revenues was $17.2 million during the fourth quarter of 2023, compared to $14.0 million during the fourth quarter of 2022, representing an increase of 22.9% year-over-year.
  • Adjusted net income1 was $1.7 million, or $0.05 per share, during the fourth quarter of 2023, compared to $7.3 million, or $0.22 per share, during the fourth quarter of 2022.
  • Adjusted EBITDA¹ was $18.2 million during the fourth quarter of 2023, compared to $18.1 million during the fourth quarter of 2022, representing an increase of 0.4% year-over-year.

Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask

Retrieved on: 
Wednesday, March 6, 2024

Featuring the AdaptiSeal™ cushion made of 100% soft silicone to adapt to various facial contours, allowing for a secure and comfortable seal throughout the night.

Key Points: 
  • Featuring the AdaptiSeal™ cushion made of 100% soft silicone to adapt to various facial contours, allowing for a secure and comfortable seal throughout the night.
  • The AirFit F40 addresses this problem by providing the necessary pressure support in a more comfortable, lower-profile full-face mask.
  • The mask is ideal for people who sleep on their side, are claustrophobic, and want the stability and seal of a universal fit mask in a minimalist design.
  • AirFit F40 masks are available in the U.S., with plans to launch in Canada, followed by EMEA, Latin America, and APAC.

Opthea to Participate in the Leerink Partners Global Biopharma Conference

Retrieved on: 
Tuesday, March 5, 2024

MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that management will participate in one-on-one investor meetings at the Leerink Partners Global Biopharma Conference being held in Miami, Florida on March 11-13, 2024.

Key Points: 
  • MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that management will participate in one-on-one investor meetings at the Leerink Partners Global Biopharma Conference being held in Miami, Florida on March 11-13, 2024.

Completion of Placement to Zijin Mining

Retrieved on: 
Tuesday, March 5, 2024

TORONTO, March 04, 2024 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX:XAM, TSX:XAM) (Xanadu or the Company) is pleased to announce that the placement of 15,185,328 fully paid ordinary shares to Jinping (Singapore) Mining Pte Ltd, a wholly owned indirect subsidiary of Zijin Mining Group Co. Ltd (Zijin), at an issue price of A$0.055 per share, completed today.

Key Points: 
  • TORONTO, March 04, 2024 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX:XAM, TSX:XAM) (Xanadu or the Company) is pleased to announce that the placement of 15,185,328 fully paid ordinary shares to Jinping (Singapore) Mining Pte Ltd, a wholly owned indirect subsidiary of Zijin Mining Group Co. Ltd (Zijin), at an issue price of A$0.055 per share, completed today.
  • Details of the proposed placement to Zijin were announced to ASX on 20 November 2023 and 8 December 2023.
  • Completion follows the satisfaction of all Conditions Precedent under the Share Subscription Agreement with Zijin, including shareholder approval on 6 February 2024, and approval by the Foreign Investment Review Board (FIRB) last week.
  • The Company has relied upon the exemption in section 602.1 of the TSX Company Manual in respect of the placement as an Eligible Interlisted Issuer.

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Retrieved on: 
Tuesday, March 5, 2024

Updated safety data from patients with HR-positive/HER2-negative/low metastatic breast cancer (MBC) treated with this innovative immuno-oncology (IO)-chemotherapy combination reveal no treatment-emergent serious adverse events.

Key Points: 
  • Updated safety data from patients with HR-positive/HER2-negative/low metastatic breast cancer (MBC) treated with this innovative immuno-oncology (IO)-chemotherapy combination reveal no treatment-emergent serious adverse events.
  • Additionally, all treatment-emergent adverse events during the safety observation period to date have been of mild severity.
  • The biologically active 30mg efti dose, previously the highest dose of efti ever tested, has demonstrated a stronger immune response and greater efficacy than lower dosing levels (1mg, 6mg) in multiple clinical trials.
  • The ongoing randomized Phase II portion of the trial, which will include up to 58 evaluable patients, is focused on whether 90mg efti dosing is safe and more efficacious than 30mg dosing.

Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform

Retrieved on: 
Monday, March 4, 2024

MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals required for consumable target production.

Key Points: 
  • MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals required for consumable target production.
  • Telix is currently validating multiple production locations of large-scale 89Zr production in the United States (U.S.) using the QIS system and select manufacturing and pharmacy partners.
  • ARTMS and Telix have been collaborating since 20202 to evaluate the potential of higher curie-scale (Ci) production of Illuccix®.
  • As part of the acquisition, Telix will also acquire the benefit of ARTMS’s production facility and clean rooms, located in Burnaby, BC (Canada).

Metallurgical Tests at Kharmagtai Show Strong Sulphide Rougher Flotation Recovery

Retrieved on: 
Monday, March 4, 2024

The sulphide rougher recovery results represent a very positive technical and economic outcome for the Kharmagtai Pre-Feasibility Study (PFS).

Key Points: 
  • The sulphide rougher recovery results represent a very positive technical and economic outcome for the Kharmagtai Pre-Feasibility Study (PFS).
  • PFS stage metallurgical test work completed for sulphide rougher process recoveries.
  • Rougher flotation tests delivered metallurgical recoveries up to 98% copper and 95% gold, at head grades up to 1.6% Cu and 2.0g/t Au at P80 grind size of 150 micron (µm).
  • It included head grade analysis and rougher flotation recovery test work on 26 samples taken from varying deposits, depths, sulphide and alteration types, using a 150 µm grind size.

Completion of Placement to Zijin Mining

Retrieved on: 
Monday, March 4, 2024

TORONTO, March 04, 2024 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX:XAM, TSX:XAM) (Xanadu or the Company) is pleased to announce that the placement of 15,185,328 fully paid ordinary shares to Jinping (Singapore) Mining Pte Ltd, a wholly owned indirect subsidiary of Zijin Mining Group Co. Ltd (Zijin), at an issue price of A$0.055 per share, completed today.

Key Points: 
  • TORONTO, March 04, 2024 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX:XAM, TSX:XAM) (Xanadu or the Company) is pleased to announce that the placement of 15,185,328 fully paid ordinary shares to Jinping (Singapore) Mining Pte Ltd, a wholly owned indirect subsidiary of Zijin Mining Group Co. Ltd (Zijin), at an issue price of A$0.055 per share, completed today.
  • Details of the proposed placement to Zijin were announced to ASX on 20 November 2023 and 8 December 2023.
  • Completion follows the satisfaction of all Conditions Precedent under the Share Subscription Agreement with Zijin, including shareholder approval on 6 February 2024, and approval by the Foreign Investment Review Board (FIRB) last week.

Puma Announces a Creative Deal to Unlock Value of its Assets in New Brunswick

Retrieved on: 
Monday, March 4, 2024

Before the execution of the Raptor Agreements, Puma was holding a 100% interest in each of the Projects.

Key Points: 
  • Before the execution of the Raptor Agreements, Puma was holding a 100% interest in each of the Projects.
  • The sale of the Chester and Turgeon Projects to Raptor will allow Puma to further monetize its copper assets and unlock their value.
  • We’re always looking to increase shareholder value and creative ways to finance and control share dilution.
  • The objective for Puma is to receive from Raptor the same consideration value as the one that it negotiated in its initial option deal with Canadian Copper, of which CAD $2M remains receivable.